Geron Corporation (Nasdaq:GERN) today announced that David L. Greenwood., executive vice president and chief financial officer, will present an update of the company’s product development programs at 2:00 p.m. PDT on Tuesday, May 13, 2008, at the Bank of America 2008 Health Care Conference in Las Vegas.

The update of Geron’s portfolio of telomerase-based anti-cancer therapies will include the inhibitor drug, GRN163L, and the therapeutic vaccine, GRNVAC1. Additionally, the presentation will include reviews of the company’s human embryonic stem cell development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1) and diabetes (GRNIC1).

The audio and slide presentation will be available at the following Web site address: http://www.veracast.com/webcasts/bas/healthcare08/id44109427.cfm. A replay will be available at this address within 24 hours of the presentation until May 30, 2008.

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.

Contacts:

Geron
David L. Greenwood, 650-473-7765
Chief Financial Officer
info@geron.com
or
Media and Investors:
Russo Partners, LLC
David Schull, 858-717-2310
david.schull@russopartnersllc.com